ReviewBMC pediatrics2026
The youngest male breast clear cell hidradenoma case: a literature review.
Review in BMC pediatrics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundClear cell hidradenoma (CCH) of the breast is an exceedingly rare benign adnexal tumor. Its clinical and radiological presentation can closely mimic malignancy, posing a significant diagnostic challenge. CASE PRESENTATION: We report a case of a 6-year-old boy presenting with a non-healing, ulcerated nodule on the left nipple-areolar complex. Ultrasonography revealed a lobulated, cystic nodule. An ultrasound-guided core needle biopsy was performed, revealing epithelial cells with clear cytoplasm, warranting excision. The lesion was completely excised. Histopathology confirmed CCH, but an involved lateral margin necessitated a successful re-excision. Immunohistochemistry (IHC) on the excised specimen showed tumor cells positive for p63, Cytokeratin, and EMA, and negative for SMA, CD10, ER, and PR. The patient remains disease-free at 12 months.
conclusionTo our knowledge, this is the youngest male reported with breast CCH. This case highlights the diagnostic pitfall where CCH mimics malignancy and underscores the critical role of histopathology and IHC, particularly p63 positivity and myoepithelial marker negativity, in reaching an accurate diagnosis. Complete surgical excision with clear margins is the definitive treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.